⌘K
Loading ticker…
As of 2026-08-21, Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) has a 3-month relative strength percentile of 71 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 48. The current market Stance is 49.9 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 5.2%, relative volume 1.43×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
RXRX is held by 22 ETFs as of May 2026. Top owner: SCHA at 0.04% weight, $9M notional. Top 3 carry $22M.
Held by 59 ETFs · $398M across latest filings · largest weight 3.51% (ARKG).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| SCHASchwab U.S. Small-Cap ETF | 0.04% | $9M | — |
| VTWO | 0.05% | $8M | — |
| VHTVanguard Health Care ETF | 0.03% | $5M | — |
| VTWG | 0.09% | $2M | — |
| AVSC | 0.05% | $1M | — |
| ESML | 0.05% | $1M | +0.01 pp |
| SCHBSchwab U.S. Broad Market ETF | 0.00% | $1M | — |
| ONEQ | 0.01% | $619K | — |
| HEAL | 1.76% | $440K | +0.15 pp |
| ESGV | 0.00% | $367K | — |
Showing 10 of 22 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RXRX Jan avg: 3.26% median: 4.77% win: 75% σ: 5.76% n: 4 2022-04-12 → 2026-07-31 | RXRX Feb avg: 8.05% median: 0.78% win: 50% σ: 24.26% n: 4 2022-04-12 → 2026-07-31 | RXRX Mar avg: -22.50% median: -22.04% win: 0% σ: 6.28% n: 4 2022-04-12 → 2026-07-31 | RXRX Apr avg: -8.31% median: -9.88% win: 40% σ: 17.48% n: 5 2022-04-12 → 2026-07-31 | RXRX May avg: 13.40% median: 3.76% win: 60% σ: 41.30% n: 5 2022-04-12 → 2026-07-31 | RXRX Jun avg: 6.41% median: 2.23% win: 60% σ: 20.25% n: 5 2022-04-12 → 2026-07-31 | RXRX Jul avg: 20.32% median: 9.33% win: 80% σ: 40.63% n: 5 2022-04-12 → 2026-07-31 | RXRX Aug avg: -11.59% median: -16.11% win: 25% σ: 26.40% n: 4 2022-04-12 → 2026-07-31 (current) | RXRX Sep avg: -4.12% median: -4.12% win: 50% σ: 7.83% n: 4 2022-04-12 → 2026-07-31 | RXRX Oct avg: -5.70% median: -2.47% win: 25% σ: 18.43% n: 4 2022-04-12 → 2026-07-31 | RXRX Nov avg: 3.65% median: 0.48% win: 50% σ: 21.22% n: 4 2022-04-12 → 2026-07-31 | RXRX Dec avg: 2.48% median: -8.02% win: 25% σ: 28.19% n: 4 2022-04-12 → 2026-07-31 |